SPOTLIGHT: ReNeuron looks to resolve FDA issues

ReNeuron is hoping that a meeting Feb. 14 with FDA officials will resolve the agency's concerns over its ReN001 stem cell therapy, which prompted the agency to put a clinical hold on the therapy. Release

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.